Atlas chapter 12 · Oncology (adjunctive)

Shiitake / Lentinan

Lentinula edodes

Historical taxonomic name: Lentinus edodes

E4-H++ — Supports the tested propositionR4 — the lentinan-centred proposition was tested across multiple randomized/prospective programmes and synthesized across independent trials. R4 does not mean that eating Shiitake has been replicated as a cancer intervention.

Proposition / claim: Historical adjunctive clinical benefit in defined oncology settings, particularly parts of the gastric-cancer literature.
Evidence owner: Lentinan, particularly the defined parenteral/intravenous historical clinical intervention. For lentinan, the historical parenteral/intravenous route is part of the evidence owner, not a footnote. Lentinan is not equivalent to eating Shiitake.
Dominant uncertainty: There are two separate dominant uncertainties. For lentinan: reconciliation of historical-positive and modern-null lentinan evidence. A later randomized phase III gastric-cancer study tested lentinan alongside a more modern treatment regimen and did not demonstrate a significant overall-survival advantage; why favourable signals from substantial historical programmes coexist with that later null result requires investigation rather than automatic rescue of the historical result. For Shiitake: whether any practical oral whole-mushroom or Shiitake-derived preparation can independently demonstrate a clinically meaningful effect rather than inheriting lentinan's evidence.

Organism: Shiitake
Tested intervention: Lentinan
Evidence target: Standardized preparation
Intervention description: Purified / highly characterized beta-glucan polysaccharide derived from L. edodes. The grade-owning historical exposure is defined lentinan administered parenterally/intravenously as an adjunct to chemotherapy in historical oncology programmes.
Population: Advanced, unresectable or recurrent gastric cancer. The grade-determining synthesis assembled 650 patients from five centrally randomized trials.
Comparator: Not specified at dossier level
Outcome: Overall survival favoured lentinan plus chemotherapy, with a reported hazard ratio of 0.80 (95% CI 0.68-0.95).
Evidence maturity (E): E4-H+
Direction: + — Supports the tested proposition
Historical flag (H): H — the grade-determining programme belongs largely to historical oncology environments.
Replication (R): R4 — the lentinan-centred proposition was tested across multiple randomized/prospective programmes and synthesized across independent trials. R4 does not mean that eating Shiitake has been replicated as a cancer intervention.
Claim Gap (CG): Claim ceiling: CG1 for lentinan-specific historical wording. CG0-1: Historical clinical studies investigated lentinan as an adjunct in gastric-cancer treatment and reported favourable outcomes. CG1: Lentinan has substantial historical adjunctive anticancer evidence. CG1-2: A Shiitake-derived polysaccharide has demonstrated clinical benefit in some historical cancer settings. CG3-4: Shiitake helps fight cancer. CG4: Eating Shiitake provides clinically proven anticancer benefits. At this point the trial and claim describe different interventions.
Evidence Transfer Vector: ETV: I / D / C / O / P / R. For the claim 'Eating Shiitake improves survival during modern cancer treatment,' the transfers include: I — lentinan to whole Shiitake; D — parenteral clinical exposure to dietary oral exposure; C — historical to modern oncology; O/P — specific studied settings to generalized cancer survival; and R — an intervention-specific programme to dietary certainty.
Taxonomic Transfer Confidence: HIGH. Historical Lentinus edodes to modern Lentinula edodes is comparatively straightforward.
Intervention Transfer Confidence: Lentinan to dietary Shiitake: LOW. Lentinan to ordinary cooked Shiitake: LOW for the historical oncology effect. Lentinan to a generic Shiitake supplement: LOW unless pharmacological equivalence is demonstrated. Historical clinical lentinan to a modern equivalent lentinan preparation: MODERATE, subject to manufacturing, dose, route and clinical-context verification.
Safety: S2, with route- and exposure-specific considerations. Shiitake is widely eaten, yet the food itself can produce adverse reactions, including Shiitake dermatitis, especially associated with raw or insufficiently cooked mushroom. Historical oncology studies provide safety observations for administered lentinan. Neither exposure automatically establishes the other's safety profile.
Conservation: C0/C+. Shiitake is widely cultivated and its global use does not depend on harvesting rare wild populations.
Resolution zone: Resolve the historical/modern lentinan discordance before determining whether another major contemporary trial is justified; maintain a separate clinical programme for whole or oral Shiitake preparations.
Next best experiment: Lentinan: do not immediately commission another large lentinan efficacy trial. First perform a proposition-level reconciliation of the historical positive programme and the later modern randomized null result, reconstructing intervention identity, manufacture, dose, route, cancer setting, background treatment, population, endpoints and trial design across the relevant studies. If that analysis identifies a credible difference capable of explaining the divergent results, the next experiment should directly test that prediction using a defined lentinan preparation under contemporary standard-of-care conditions. If no such explanation survives scrutiny, the modern null result must retain its evidential weight. Shiitake: if the claim concerns whole mushroom or an oral Shiitake extract, do not use lentinan as a proxy. Characterize the oral preparation, establish relevant exposure, and test that preparation against the claimed human outcome. Two uncertainties require two experiments.
Primary references: Oba K et al. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer Research. 2009;29(7):2739-2745. PMID 19596954. Five centrally randomized trials; 650 patients; overall survival HR 0.80 (95% CI 0.68-0.95).
Taguchi T et al. Randomized clinical work in advanced gastric cancer included intravenous lentinan, commonly 2 mg weekly, alongside chemotherapy and reported survival-related outcomes on long-term follow-up. PMID 3121179.
Zhang M et al. Lentinan combined with chemotherapy for advanced gastric cancer: a meta-analysis of prospective controlled studies. OncoTargets and Therapy. 2017. PMID 28940986. Seventeen prospective controlled studies; 1,423 patients; the authors cautioned that evidence for sustained survival benefit remained uncertain.
Later systematic reviews have assembled larger randomized literatures for injectable lentinan plus chemotherapy, reinforcing the existence of a substantial intervention-specific programme while not establishing equivalence to dietary Shiitake or answering all contemporary hard-endpoint questions.
Source chapter: Chapter 12, The Fungal Evidence Atlas